Search
01/05/2025
Methylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia
Segura, AG, Prohens, L, Julià, L, Amoretti, S, Ribero, M, Pino-Camacho, L, Cano-Escalera, G, Mane, A, Rodriguez-Jimenez, R, Roldan, A, Sarró, S, Ibañez, A, Usall, J, Lobo, A, Garcia-Rizo, C, Cuesta, MJ, Parellada, M, González-Pinto, A, Berrocoso, E, Mas, S, Rodriguez, N, Perez-Ramos, A, Salmeron, S, González-Peñas, J, Gurriarán, X, Farré, A, Pousa, E, Zorrilla, I, Mar-Barrutia, L, Trabsa, A, Martinez, L, Sánchez-Cabezudo, A, Jiménez-López, E, Pomarol-Clotet, E, Salvador, R, Butjosa, A, Elena, RA, Moreno-Izco, L, Torres, AMS, Saiz, J, León-Quismondo, L, Rivero, O, González-Blanco, L, De-la-Camára, C, Bernardo, M. Methylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2025; 94DOI:10.1016/j.euroneuro.2025.02.003. PMID:39956014. IF:6.700(Q1/1D).
01/05/2025
From Genetics to Psychosocial Functioning: Unraveling the Mediating Roles of Cognitive Reserve, Cognition, and Negative Symptoms in First-Episode Psychosis
Forte, MF, Clougher, D, Segura, AG, Mezquida, G, Sánchez-Torres, AM, Vieta, E, Garriga, M, Lobo, A, González-Pinto, AM, Diaz-Caneja, CM, Roldan, A, Martínez-Arán, A, de la Serna, E, Mané, A, Mas, S, Torrent, C, Allot, K, Bernardo, M, Amoretti, S, PEPs Grp. From Genetics to Psychosocial Functioning: Unraveling the Mediating Roles of Cognitive Reserve, Cognition, and Negative Symptoms in First-Episode Psychosis. ACTA PSYCHIATRICA SCANDINAVICA. 2025; 151(5)DOI:10.1111/acps.13779. PMID:39722475. IF:5.000(Q1/2D).
01/05/2025
A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study
Molero, P, Ibañez, A, de Diego-Adeliño, J, Ramos-Quiroga, JA, Dorado, MG, Rengel, PML, Saiz, PA. A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study. ADVANCES IN THERAPY. 2025; 42(5)DOI:10.1007/s12325-025-03149-z. PMID:40106175. IF:4.000(Q1/3D).
01/05/2025
Integral Cognitive Remediation (INCREM) as a Strategy to Enhance Long-Term Psychosocial Recovery in Depression: A Multicentric Randomized Controlled Trial
Portella, M, Vicent-Gil, M, Vall, G, Legido, T, Mur, M, Guarch, J, de Diego-Adeliño, J, González-Simarro, S, Raventós, B, Vera, J, Gawron, L, Bonnin, CD, Clavé, N, Cámara-Gómez, RM, Kiskeri-Aiguabella, A, Romero-López, M, Rodríguez-Pérez, I, Carrasco, J, Alemany, C, Alvarez, NC. Integral Cognitive Remediation (INCREM) as a Strategy to Enhance Long-Term Psychosocial Recovery in Depression: A Multicentric Randomized Controlled Trial. BIOLOGICAL PSYCHIATRY. 2025; 97(9)DOI:. PMID:. IF:9.000(Q1/1D).
01/05/2025
Mindfulness-Based Cognitive Therapy Neurobiology During Self-Referential Processing in Treatment-Resistant Obsessive-Compulsive Disorder
Porta-Casteràs, D, Cano, M, Alonso, P, Vicent-Gil, M, de la Peña-Arteaga, V, Miquel-Giner, N, Martínez-Zalacaín, I, Mar-Barrutia, L, López-Sola, M, Andrews-Hanna, JR, Soriano-Mas, C, Cardoner, N, López-Solà, C, Serra-Blasco, M. Mindfulness-Based Cognitive Therapy Neurobiology During Self-Referential Processing in Treatment-Resistant Obsessive-Compulsive Disorder. BIOLOGICAL PSYCHIATRY. 2025; 97(9)DOI:. PMID:. IF:9.000(Q1/1D).
18/04/2025
Evaluating the efficacy of radically open dialectical behavior therapy (RO-DBT) in patients with anorexia nervosa: study protocol for a randomized controlled clinical trial
Avila-Parcet, A, Martín-Blanco, A, Gawron, L, Cano, M, Peña-Arteaga, VD, Carceller-Sindreu, M, Soler, J, Portella, MJ, Faustino, G, Cardoner, N, Farrés, CCI. Evaluating the efficacy of radically open dialectical behavior therapy (RO-DBT) in patients with anorexia nervosa: study protocol for a randomized controlled clinical trial. BMC Psychiatry. 2025; 25(1)DOI:10.1186/s12888-025-06854-9. PMID:40251556. IF:3.600(Q1/3D).
12/04/2025
Sex-based differences in Jumping to Conclusions: a multidimensional analysis of first-episode psychosis
Díaz-Cutraro, L, Verdaguer-Rodríguez, M, García-Mieres, H, Ferrer-Quintero, M, López-Carrilero, R, Palma-Sevillano, C, Lamarca, M, Espinosa, V, Barrigón, ML, González-Higueras, F, Pousa, E, Grasa, E, Lorente-Rovira, E, Gutiérrez-Zotes, A, Barajas, A, Ruiz-Delgado, I, Cid, J, Moritz, S, Rico, J, Sevilla-Llewellyn-Jones, J, Haro, JM, Ochoa, S. Sex-based differences in Jumping to Conclusions: a multidimensional analysis of first-episode psychosis. SCHIZOPHRENIA. 2025; 11(1)DOI:10.1038/s41537-025-00579-0. PMID:40221473. IF:4.100(Q1/2D).
01/04/2025
Scale to measure dialectical thinking from dialectical behavior therapy perspective.
Soler, J, Arqueros, M, Schmidt, C, Otero, D, Soria-Madrid, A, Campins, MJ, Catalan, A, Casellas, E, Espeso, R, Pascual, JC. Scale to measure dialectical thinking from dialectical behavior therapy perspective.. EUROPEAN JOURNAL OF PSYCHIATRY. 2025; 39(2)DOI:10.1016/j.ejpsy.2025.100305. PMID:. IF:1.500(Q3/7D).
01/04/2025
Alcohol and Other Substance Screening in Bariatric Surgery Candidates: Utility of Self-Report and Toxicology Tests, Including Ethyl-Glucoronide
Cañizares, S, Nuño, L, Barrio, P, Forner-Puntonet, M, Gavotti, C, Monràs, M, Gavín, P, Navinés, R, Flores, L, Barrios, M, Andreu, A, Molero, J, Jimenez, A, Vidal, J, Lligoña, A. Alcohol and Other Substance Screening in Bariatric Surgery Candidates: Utility of Self-Report and Toxicology Tests, Including Ethyl-Glucoronide. OBESITY SURGERY. 2025; 35(4)DOI:10.1007/s11695-025-07774-z. PMID:40072740. IF:3.100(Q1/2D).
19/03/2025
Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
Vicent-Gil, M, Trujols, J, Sagues, T, Serra-Blasco, M, Navarra-Ventura, G, Mantellini, CL, Crivillés, S, Portella, MJ, Cardoner, N. Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder. Annals of General Psychiatry. 2025; 24(1)DOI:10.1186/s12991-025-00552-2. PMID:40108685. IF:3.100(Q2/4D).
07/02/2025
Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness
Cardoner, N, Gutiérrez-Rojas, L, Saiz, P, Lahera, G, alvarez-Mon, MA, Ortega, PA, Pérez-Páramo, M. Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness. Frontiers in Pharmacology. 2025; 16DOI:10.3389/fphar.2025.1483770. PMID:39989902. IF:4.800(Q1/2D).
01/02/2025
Mapping punishment avoidance learning deficits in non-suicidal self-injury in young adults with and without borderline personality disorder: An fMRI study
Nicolaou, S, Pascual, JC, Soler, J, Ortega, G, Marco-Pallarés, J, Vega, D. Mapping punishment avoidance learning deficits in non-suicidal self-injury in young adults with and without borderline personality disorder: An fMRI study. JOURNAL OF AFFECTIVE DISORDERS. 2025; 370DOI:10.1016/j.jad.2024.11.026. PMID:39542117. IF:4.900(Q1/2D).
01/01/2025
Linking cognitive function and biological markers in depression: Can IL-6 plasma levels and attention domain be used as an ensemble classification system?
Portella, MJ, Arteaga-Henríquez, G, de Diego-Adeliño, J, Trujols, J, Puigdemont, D, Pérez, J, Alemany, C, Carrasco-Hernández, J, Udina, M, Cardoner, N, Vicent-Gil, M. Linking cognitive function and biological markers in depression: Can IL-6 plasma levels and attention domain be used as an ensemble classification system?. GENERAL HOSPITAL PSYCHIATRY. 2025; 92DOI:10.1016/j.genhosppsych.2024.10.003. PMID:39395857. IF:3.700(Q1/3D).
01/01/2025
Mobile Therapeutic Attention for Treatment-Resistant Schizophrenia (m-RESIST) Solution for Improving Clinical and Functional Outcomes in Treatment-Resistant Schizophrenia: Prospective, Multicenter Efficacy Study
Seppälä, J, Grasa, E, Alonso-Solis, A, Roldan-Bejarano, A, Haapea, M, Isohanni, M, Miettunen, J, Mendivelso, JC, Almazán, C, Rubinstein, K, Caspi, A, Unoka, Z, Farkas, K, Reixach, E, Berdun, J, Usall, J, Ochoa, S, Corripio, I, Jääskeläinen, E. Mobile Therapeutic Attention for Treatment-Resistant Schizophrenia (m-RESIST) Solution for Improving Clinical and Functional Outcomes in Treatment-Resistant Schizophrenia: Prospective, Multicenter Efficacy Study. Jmir Human Factors. 2025; 12DOI:10.2196/67659. PMID:40372941. IF:(Q/D).
01/12/2024
Cancer characteristics in patients with schizophrenia: a 25-year retrospective analysis
Casanovas, F, Dinamarca, F, Posso, M, Mané, A, Oller, S, Córcoles, D, Macià, F, Sala, M, Pérez-Sola, V, Ruiz, AI. Cancer characteristics in patients with schizophrenia: a 25-year retrospective analysis. PSYCHIATRY RESEARCH. 2024; 342DOI:10.1016/j.psychres.2024.116206. PMID:39321636. IF:3.900(Q1/2D).
01/12/2024
Orbitofrontal cortex hypergyrification in hallucinating schizophrenia patients: Surface ratio as a promising brain biomarker
Núñez, C, Stephan-Otto, C, Roldán, A, Grasa, EM, Escartí, MJ, García-Iturrospe, EJA, García-Martí, G, de la Iglesia-vaya, M, Nacher, J, Portella, MJ, Corripio, I. Orbitofrontal cortex hypergyrification in hallucinating schizophrenia patients: Surface ratio as a promising brain biomarker. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024; 89DOI:10.1016/j.euroneuro.2024.09.006. PMID:39341083. IF:6.700(Q1/1D).
01/11/2024
Electroconvulsive therapy and cognitive performance from the Global ECT MRI Research Collaboration
Kiebs, M, Farrar, DC, Yrondi, A, Cardoner, N, Tuovinen, N, Redlich, R, Dannlowski, U, Soriano-Mas, C, Dols, A, Takamiya, A, Tendolkar, I, Narr, KL, Espinoza, R, Laroy, M, van Eijndhoven, P, Verwijk, E, van Waarde, J, Verdijk, J, Maier, HB, Nordanskog, P, van Wingen, G, van Diermen, L, Emsell, L, Bouckaert, F, Repple, J, Camprodon, JA, Wade, BSC, Donaldson, KT, Oltedal, L, Kessler, U, Hammar, A, Sienaert, P, Hebbrecht, K, Urretavizcaya, M, Belge, JB, Argyelan, M, Baradits, M, Obbels, J, Draganski, B, Philipsen, A, Sartorius, A, Rhebergen, D, Ousdal, OT, Hurlemann, R, McClintock, S, Erhardt, EB, Abbott, CC. Electroconvulsive therapy and cognitive performance from the Global ECT MRI Research Collaboration. JOURNAL OF PSYCHIATRIC RESEARCH. 2024; 179DOI:10.1016/j.jpsychires.2024.09.013. PMID:39312853. IF:3.200(Q2/4D).
01/11/2024
Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode
Jordà-Baleri, T, Garriga, M, Mezquida, G, Cuesta, MJ, Martinez-Aran, A, Garcia-Rizo, C, Lobo, A, González-Pinto, A, Diaz-Caneja, CM, Roldán, A, Vieta, E, Baeza, I, Trabsa, A, Montalvo, I, Tortorella, A, Menculini, G, Verdolini, N, Ramos-Quiroga, JA, Torres, AMS, Bernardo, M, Amoretti, S. Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode. PSYCHONEUROENDOCRINOLOGY. 2024; 169DOI:10.1016/j.psyneuen.2024.107112. PMID:39106582. IF:3.600(Q1/3D).
01/11/2024
EMDR therapy vs. supportive therapy as adjunctive treatment in trauma-exposed bipolar patients: A randomised controlled trial
Hogg, B, Radua, J, Gardoki-Souto, I, Fontana-McNally, M, Lupo, W, Reinares, M, Jimenez, E, Madre, M, Blanco-Presas, L, Cortizo, R, Massó-Rodriguez, A, Castaño, J, Argila, I, Castro-Rodriguez, JI, Comes, M, Macias, C, Sánchez-González, R, Mur-Mila, E, Novo, P, Rosa, AR, Vieta, E, Padberg, F, Pérez-Solà, V, Valiente-Gómez, A, Moreno-Alcázar, A, Amann, BL. EMDR therapy vs. supportive therapy as adjunctive treatment in trauma-exposed bipolar patients: A randomised controlled trial. SPANISH JOURNAL OF PSYCHIATRY AND MENTAL HEALTH. 2024; 17(4)DOI:10.1016/j.sjpmh.2023.11.005. PMID:38061553. IF:2.800(Q2/4D).
05/10/2024
Probing the oral-brain connection: oral microbiome patterns in a large community cohort with anxiety, depression, and trauma symptoms, and periodontal outcomes
Malan-Müller, S, Vidal, R, O'Shea, E, Montero, E, Figuero, E, Zorrilla, I, de Diego-Adeliño, J, Cano, M, García-Portilla, MP, González-Pinto, A, Leza, JC. Probing the oral-brain connection: oral microbiome patterns in a large community cohort with anxiety, depression, and trauma symptoms, and periodontal outcomes. Translational Psychiatry. 2024; 14(1)DOI:10.1038/s41398-024-03122-4. PMID:39368974. IF:6.200(Q1/1D).
01/10/2024
Contextual-compassion training for borderline personality disorder with long lasting symptoms: A randomized clinical trial
Casellas-Pujol, E, Soler, J, Schmidt, C, Soria-Madrid, A, Elices, M, Pascual, JC. Contextual-compassion training for borderline personality disorder with long lasting symptoms: A randomized clinical trial. Journal of Contextual Behavioral Science. 2024; 34DOI:10.1016/j.jcbs.2024.100846. PMID:. IF:3.000(Q1/3D).
01/10/2024
A pilot, randomized, three-arm, dose-finding, placebo-controlled, parallel study to evaluate the use of nabiximols (THC plus CBD, Sativex®) for cannabis detoxification treatment versus treatment as usual
Bonifacio, DM, Rodríguez, MP, Perelló, PM, Hurtado, JC, Albet, JT, Tutusaus, XR, Arbós, RMA. A pilot, randomized, three-arm, dose-finding, placebo-controlled, parallel study to evaluate the use of nabiximols (THC plus CBD, Sativex®) for cannabis detoxification treatment versus treatment as usual. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2024; 135DOI:. PMID:. IF:3.300(Q2/4D).
02/09/2024
How does mindfulness skills training work to improve emotion dysregulation in borderline personality disorder?
Schmidt, C, Soler, J, Vega, D, Nicolaou, S, Arias, L, Pascual, JC. How does mindfulness skills training work to improve emotion dysregulation in borderline personality disorder?. Borderline Personality Disorder and Emotion Dysregulation. 2024; 11(1)DOI:10.1186/s40479-024-00265-0. PMID:39218933. IF:2.700(Q2/4D).
01/09/2024
Cognitive insight in first-episode psychosis: Exploring the complex relationship between executive functions and social cognition
López-Carrilero, R, Lo Monaco, M, Frígola-Capell, E, Ferrer-Quintero, M, Díaz-Cutraro, L, Verdaguer-Rodríguez, M, García-Mieres, H, Vila-Badia, R, Punsoda-Puche, P, Birulés, I, Peláez, T, Pousa, E, Grasa, E, Barajas, A, Ruiz-Delgado, I, Barrigón, ML, Gonzalez-Higueras, F, Lorente-Rovira, E, Gutiérrez-Zotes, A, Cid, J, Legido, T, Ayesa-Arriola, R, Moritz, S, Ochoa, S. Cognitive insight in first-episode psychosis: Exploring the complex relationship between executive functions and social cognition. SPANISH JOURNAL OF PSYCHIATRY AND MENTAL HEALTH. 2024; 17(3)DOI:10.1016/j.sjpmh.2024.01.002. PMID:38219901. IF:2.800(Q2/4D).
01/09/2024
Is it possible to predict hospitalisation during intensive home treatment? A retrospective cohort study
Martín-Blanco, A, González-Fernández, A, Vieira, S, Farré, A, Isern, C, Avila-Parcet, A, Gausachs, E, Patrizi, B, Cardoner, N, Portella, MJ. Is it possible to predict hospitalisation during intensive home treatment? A retrospective cohort study. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2024; 28(3-4)DOI:10.1080/13651501.2025.2461798. PMID:39954709. IF:2.700(Q2/4D).
01/08/2024
Outcomes of Bariatric Surgery in Patients with Schizophrenia
Miñambres, I, Rubio-Herrera, MA, Nicolau, J, Milad, C, Morales, MJ, Bueno, M, Calañas, A, Carceller-Sindreu, M, de Hollanda, A. Outcomes of Bariatric Surgery in Patients with Schizophrenia. Nutrients. 2024; 16(15)DOI:10.3390/nu16152487. PMID:39125367. IF:5.000(Q1/2D).
01/08/2024
Cortical and Subcortical Brain Alterations in Specific Phobia and Its Animal and Blood-Injection-Injury Subtypes: A Mega-Analysis From the ENIGMA Anxiety Working Group
Hilbert, K, Boeken, OJ, Langhammer, T, Groenewold, NA, Bas-Hoogendam, JM, Aghajani, M, Zugman, A, Åhs, F, Arolt, V, Beesdo-Baum, K, Björkstrand, J, Blackford, JU, Blanco-Hinojo, L, Böhnlein, J, Bülow, R, Cano, M, Cardoner, N, Caseras, X, Dannlowski, U, Domschke, K, Fehm, L, Feola, B, Fredrikson, M, Goossens, L, Grabe, HJ, Grotegerd, D, Gur, RE, Hamm, AO, Harrewijn, A, Heinig, I, Herrmann, MJ, Hofmann, D, Jackowski, AP, Jansen, A, Kaczkurkin, AN, Kindt, M, Kingsley, EN, Kircher, T, Klahn, AL, Koelkebeck, K, Krug, A, Kugel, H, Larsen, B, Leehr, EJ, Leonhardt, L, Lotze, M, Margraf, J, Michalowski, J, Muehlhan, M, Nenadic, I, Pan, PM, Pauli, P, Peñate, W, Pittig, A, Plag, J, Pujol, J, Richter, J, Rivero, FL, Salum, GA, Satterthwaite, TD, Schäfer, A, Schäfer, J, Schienle, A, Schneider, S, Schrammen, E, Schruers, K, Schulz, SM, Seidl, E, Stark, RM, Stein, F, Straube, B, Straube, T, Ströhle, A, Suchan, B, Thomopoulos, SI, Ventura-Bort, C, Visser, R, Völzke, H, Wabnegger, A, Wannemüller, A, Wendt, J, Wiemer, J, Wittchen, HU, Wittfeld, K, Wright, B, Yang, Y, Zilverstand, A, Zwanzger, P, Veltman, DJ, Winkler, AM, Pine, DS, Jahanshad, N, Thompson, PM, Stein, DJ, Van der Wee, NJ, Lueken, U. Cortical and Subcortical Brain Alterations in Specific Phobia and Its Animal and Blood-Injection-Injury Subtypes: A Mega-Analysis From the ENIGMA Anxiety Working Group. AMERICAN JOURNAL OF PSYCHIATRY. 2024; 181(8)DOI:10.1176/appi.ajp.20230032. PMID:38859702. IF:14.700(Q1/1D).
01/05/2024
Non-fatal suicide behaviours across phases in the COVID-19 pandemic: a population-based study in a Catalan cohort
Serrano-Gimeno, V, Diestre, A, Agustin-Alcain, M, Portella, MJ, de Diego-Adelino, J, Tiana, T, Cheddi, N, Distefano, A, Dominguez, G, Arias, M, Cardoner, V, Puigdemont, D, Perez, V, Cardoner, N. Non-fatal suicide behaviours across phases in the COVID-19 pandemic: a population-based study in a Catalan cohort. LANCET PSYCHIATRY. 2024; 11(5)DOI:10.1016/S2215-0366(24)00065-8. PMID:38631785. IF:24.800(Q1/1D).
01/04/2024
Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression
Young, AH, Baune, BT, Cardoner, N, Frey, R, Ito, T, Kambarov, Y, Lacerda, A, Rive, B, von Holt, C, Oliveira-Maia, AJ. Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression. EUROPEAN PSYCHIATRY. 2024; 67DOI:10.1192/j.eurpsy.2024.749. PMID:. IF:6.700(Q1/1D).
01/04/2022
Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat
Querol-Vilaseca, M, Sirisi, S, Molina-Porcel, L, Molina, B, Pegueroles, J, Ferrer-Raventos, P, Nunez-Llaves, R, Dols-Icardo, O, Balasa, M, Iulita, MF, Blesa, R, Belbin, O, Clarimon, J, Fortea, J, Gelpi, E, Sanchez-Valle, R, Lleo, A. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2022; 48(3)DOI:10.1111/nan.12781. PMID:34825396. IF:5.000(Q1/2D).
01/03/2022
Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis
Hostettler, IC, Wilson, D, Fiebelkorn, CA, Aum, D, Ameriso, SF, Eberbach, F, Beitzke, M, Kleinig, T, Phan, T, Marchina, S, Schneckenburger, R, Carmona-Iragui, M, Charidimou, A, Mourand, I, Parreira, S, Ambler, G, Jager, HR, Singhal, S, Ly, J, Ma, H, Touze, E, Geraldes, R, Fonseca, AC, Melo, T, Labauge, P, Lefevre, PH, Viswanathan, A, Greenberg, SM, Fortea, J, Apoil, M, Boulanger, M, Viader, F, Kumar, S, Srikanth, V, Khurram, A, Fazekas, F, Bruno, V, Zipfel, GJ, Refai, D, Rabinstein, A, Graff-Radford, J, Werring, DJ. Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis. JOURNAL OF NEUROLOGY. 2022; 269(3)DOI:10.1007/s00415-021-10706-3. PMID:34272978. IF:6.000(Q1/2D).
27/01/2022
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid
Gobom, J, Parnetti, L, Rosa-Neto, P, Vyhnalek, M, Gauthier, S, Cataldi, S, Lerch, O, Laczo, J, Cechova, K, Clarin, M, Benet, AI, Pascoal, TA, Rahmouni, N, Vandijck, M, Huyck, E, Le Bastard, N, Stevenson, J, Chamoun, M, Alcolea, D, Lleo, A, Andreasson, U, Verbeek, MM, Bellomo, G, Rinaldi, R, Ashton, N, Zetterberg, H, Sheardova, K, Hort, J, Blennow, K. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2022; 60(2)DOI:10.1515/cclm-2021-0651. PMID:34773730. IF:6.800(Q1/2D).
01/01/2022
Preliminary study of the temporal variables of continuous speech in patients with neurodegenerative syndromes of the frontotemporal lobar degeneration spectrum
Baque, L, Machuca, MJ, Santos-Santos, MA. Preliminary study of the temporal variables of continuous speech in patients with neurodegenerative syndromes of the frontotemporal lobar degeneration spectrum. REVISTA DE NEUROLOGIA. 2022; 74(2)DOI:10.33588/rn.7402.2021197. PMID:35014018. IF:1.200(Q4/10D).
10/12/2021
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
Zhu, N, Santos-Santos, M, Illan-Gala, I, Montal, V, Estelles, T, Barroeta, I, Altuna, M, Arranz, J, Munoz, L, Belbin, O, Sala, I, Sanchez-Saudinos, MB, Subirana, A, Videla, L, Pegueroles, J, Blesa, R, Clarimon, J, Carmona-Iragui, M, Fortea, J, Lleo, A, Alcolea, D. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Translational Neurodegeneration. 2021; 10(1)DOI:10.1186/s40035-021-00275-w. PMID:34893073. IF:9.883(Q1/1D).
01/12/2021
Association of cortical microstructure with amyloid-beta and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults
Rodriguez-Vieitez, E, Montal, V, Sepulcre, J, Lois, C, Hanseeuw, B, Vilaplana, E, Schultz, AP, Properzi, MJ, Scott, MR, Amariglio, R, Papp, KV, Marshall, GA, Fortea, J, Johnson, KA, Sperling, RA, Vannini, P. Association of cortical microstructure with amyloid-beta and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. MOLECULAR PSYCHIATRY. 2021; 26(12)DOI:10.1038/s41380-021-01290-z. PMID:34588623. IF:13.437(Q1/1D).
01/12/2021
Specific Susceptibility to COVID-19 in Adults with Down Syndrome (Mar, 10.1007/s12017-021-08651-5, 2021)
Illouz, T, Biragyn, A, Frenkel-Morgenstern, M, Weissberg, O, Gorohovski, A, Merzon, E, Green, I, Iulita, F, Flores-Aguilar, L, Dierssen, M, De Toma, I, Lifshitz, H, Antonarakis, SE, Yu, EE, Herault, Y, Potier, MC, Botte, A, Roper, R, Sredni, B, Sarid, R, London, J, Mobley, W, Strydom, A, Okun, E. Specific Susceptibility to COVID-19 in Adults with Down Syndrome (Mar, 10.1007/s12017-021-08651-5, 2021). NEUROMOLECULAR MEDICINE. 2021; 23(4)DOI:10.1007/s12017-021-08657-z. PMID:33948879. IF:4.103(Q2/5D).
01/12/2021
Atypical astroglial pTDP-43 pathology in astroglial predominant tauopathy
Gelpi, E, Aldecoa, I, Lopez-Villegas, D, Abellan-Vidal, MT, Mercadel-Fananas, P, Fortea, J, Ribosa, R, Morenas, E, Gomez-Anson, B, Molina-Porcel, L, Ximelis, T, Borrego, S, Antonell, A, Rovelet-Lecrux, A, Klotz, S, Andres-Benito, P, Sanchez-Valle, R, Ferrer, I. Atypical astroglial pTDP-43 pathology in astroglial predominant tauopathy. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2021; 47(7)DOI:10.1111/nan.12707. PMID:33730418. IF:6.250(Q1/2D).
01/12/2021
Specific Susceptibility to COVID-19 in Adults with Down Syndrome
Illouz, T, Biragyn, A, Frenkel-Morgenstern, M, Weissberg, O, Gorohovski, A, Merzon, E, Green, I, Iulita, F, Flores-Aguilar, L, Sotos, MDD, De Toma, I, Lifshitz, H, Antonarakis, SE, Yu, E, Herault, Y, Potier, MC, Botte, A, Roper, R, Sredni, B, Sarid, R, London, J, Mobley, W, Strydom, A, Okun, E. Specific Susceptibility to COVID-19 in Adults with Down Syndrome. NEUROMOLECULAR MEDICINE. 2021; 23(4)DOI:10.1007/s12017-021-08651-5. PMID:33660221. IF:4.103(Q2/5D).
16/11/2021
Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy (vol 13, 160, 2021)
De Kort, AM, Kuiperij, HB, Alcolea, D, Kersten, I, Versleijen, AAM, Greenberg, SM, Stoops, E, Schreuder, FHBM, Klijn, CJM, Lleo, A, Claassen, JAHR, Verbeek, MM. Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy (vol 13, 160, 2021). Alzheimers Research & Therapy. 2021; 13(1)DOI:10.1186/s13195-021-00929-x. PMID:34784952. IF:8.831(Q1/1D).
01/11/2021
Alternative platelet activation pathways and their role in neurodegenerative diseases
Ferrer-Raventos, P, Beyer, K. Alternative platelet activation pathways and their role in neurodegenerative diseases. NEUROBIOLOGY OF DISEASE. 2021; 159DOI:10.1016/j.nbd.2021.105512. PMID:34537329. IF:7.046(Q1/2D).
01/11/2021
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias
Alcolea, D, Delaby, C, Munoz, L, Torres, S, Estelles, T, Zhu, N, Barroeta, I, Carmona-Iragui, M, Illan-Gala, I, Santos-Santos, MA, Altuna, M, Sala, I, Sanchez-Saudinos, MB, Videla, L, Valldeneu, S, Subirana, A, Pegueroles, J, Hirtz, C, Vialaret, J, Lehmann, S, Karikari, TK, Ashton, NJ, Blennow, K, Zetterberg, H, Belbin, O, Blesa, R, Clarimon, J, Fortea, J, Lleo, A. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2021; 92(11)DOI:10.1136/jnnp-2021-326603. PMID:34103344. IF:13.654(Q1/1D).
01/11/2021
Cytokines as new biomarkers of skin wound vitality
Peyron, PA, Colomb, S, Becas, D, Adriansen, A, Gauchotte, G, Tiers, L, Marin, G, Lehmann, S, Baccino, E, Delaby, C, Hirtz, C. Cytokines as new biomarkers of skin wound vitality. INTERNATIONAL JOURNAL OF LEGAL MEDICINE. 2021; 135(6)DOI:10.1007/s00414-021-02659-z. PMID:34313846. IF:2.791(Q1/3D).
01/11/2021
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J, Zaman, SH, Hartley, S, Rafii, MS, Head, E, Carmona-Iragui, M. Alzheimer's disease associated with Down syndrome: a genetic form of dementia. LANCET NEUROLOGY. 2021; 20(11)DOI:10.1016/S1474-4422(21)00245-3. PMID:34687637. IF:59.935(Q1/1D).
01/11/2021
Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort
Xu, J, Green, R, Kim, M, Lord, J, Ebshiana, A, Westwood, S, Baird, AL, Nevado-Holgado, AJ, Shi, L, Hye, A, Snowden, SG, Bos, I, Vos, SJB, Vandenberghe, R, Teunissen, CE, Kate, MT, Scheltens, P, Gabel, S, Meersmans, K, Blin, O, Richardson, J, De Roeck, EE, Engelborghs, S, Sleegers, K, Bordet, R, Rami, L, Kettunen, P, Tsolaki, M, Verhey, FRJ, Alcolea, D, Lleo, A, Peyratout, G, Tainta, M, Johannsen, P, Freund-Levi, Y, Froelich, L, Dobricic, V, Frisoni, GB, Molinuevo, JL, Wallin, A, Popp, J, Martinez-Lage, P, Bertram, L, Blennow, K, Zetterberg, H, Streffer, J, Visser, PJ, Lovestone, S, Proitsi, P, Legido-Quigley, C. Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines. 2021; 9(11)DOI:10.3390/biomedicines9111610. PMID:34829839. IF:4.757(Q2/4D).
18/10/2021
Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease
Ximelis, T, Marin-Moreno, A, Espinosa, JC, Erana, H, Charco, JM, Hernandez, I, Riveira, C, Alcolea, D, Gonzalez-Roca, E, Aldecoa, I, Molina-Porcel, L, Parchi, P, Rossi, M, Castilla, J, Ruiz-Garcia, R, Gelpi, E, Torres, JM, Sanchez-Valle, R. Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. Alzheimers Research & Therapy. 2021; 13(1)DOI:10.1186/s13195-021-00912-6. PMID:34663460. IF:8.831(Q1/1D).
04/10/2021
Divergent connectomic organization delineates genetic evolutionary traits in the human brain
Bueicheku, E, Gonzalez-de-Echavarri, JM, Ortiz-Teran, L, Montal, V, Uquillas, FD, De Marcos, L, Orwig, W, Kim, CM, Ortiz-Teran, E, Basaia, S, Diez, I, Sepulcre, J. Divergent connectomic organization delineates genetic evolutionary traits in the human brain. Scientific Reports. 2021; 11(1)DOI:10.1038/s41598-021-99082-6. PMID:34608211. IF:4.997(Q2/3D).
26/09/2021
Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease
Barranco, N, Pla, V, Alcolea, D, Sanchez-Dominguez, I, Fischer-Colbrie, R, Ferrer, I, Lleo, A, Aguado, F. Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. Translational Neurodegeneration. 2021; 10(1)DOI:10.1186/s40035-021-00263-0. PMID:34565482. IF:9.883(Q1/1D).
24/09/2021
Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy
De Kort, AM, Kuiperij, HB, Alcolea, D, Kersten, I, Versleijen, AAM, Greenberg, SM, Stoops, E, Schreuder, FHBM, Klijn, CJM, Lleo, A, Claassen, JAHR, Verbeek, MM. Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. Alzheimers Research & Therapy. 2021; 13(1)DOI:10.1186/s13195-021-00899-0. PMID:34560885. IF:8.831(Q1/1D).
01/09/2021
CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
Tijms, BM, Gobom, J, Teunissen, C, Dobricic, V, Tsolaki, M, Verhey, F, Popp, J, Martinez-Lage, P, Vandenberghe, R, Lleo, A, Molinuevo, JL, Engelborghs, S, Freund-Levi, Y, Froelich, L, Bertram, L, Lovestone, S, Streffer, J, Vos, S, Blennow, K, Scheltens, P, Zetterberg, H, Visser, PJ, ADNI. CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes. 2021; 9(3)DOI:10.3390/proteomes9030036. PMID:34449748. IF:(Q/D).
01/09/2021
Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain
Ledreux, A, Thomas, S, Hamlett, ED, Trautman, C, Gilmore, A, Hager, ER, Paredes, DA, Margittai, M, Fortea, J, Granholm, AC. Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain. Journal of Clinical Medicine. 2021; 10(17)DOI:10.3390/jcm10173931. PMID:34501378. IF:4.964(Q2/4D).
01/09/2021
Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes
Horta-Barba, A, Pagonabarraga, J, Martinez-Horta, S, Busteed, L, Pascual-Sedano, B, Illan-Gala, I, Marin-Lahoz, J, Aracil-Bolanos, I, Perez-Perez, J, Sampedro, F, Bejr-Kasem, H, Kulisevsky, J. Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. JOURNAL OF NEUROLOGY. 2021; 268(9)DOI:10.1007/s00415-021-10511-y. PMID:33704556. IF:6.682(Q1/2D).
01/09/2021
Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome
Montal, V, Barroeta, I, Bejanin, A, Pegueroles, J, Carmona-Iragui, M, Altuna, M, Benejam, B, Videla, L, Fernandez, S, Padilla, C, Aranha, MR, Iulita, MF, Vidal-Pineiro, D, Alcolea, D, Blesa, R, Lleo, A, Fortea, J. Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. ANNALS OF NEUROLOGY. 2021; 90(3)DOI:10.1002/ana.26178. PMID:34309066. IF:11.274(Q1/1D).
19/08/2021
Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients
Solana, E, Martinez-Heras, E, Montal, V, Vilaplana, E, Lopez-Soley, E, Radua, J, Sola-Valls, N, Montejo, C, Blanco, Y, Pulido-Valdeolivas, I, Sepulveda, M, Andorra, M, Berenguer, J, Villoslada, P, Martinez-Lapiscina, EH, Prados, F, Saiz, A, Fortea, J, Llufriu, S. Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. Scientific Reports. 2021; 11(1)DOI:10.1038/s41598-021-96132-x. PMID:34413373. IF:4.997(Q2/3D).
01/08/2021
Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome
de Asua, DR, Mayer, MA, Ortega, MD, Borrel, JM, Bermejo, TD, Gonzalez-Lamuno, D, Manso, C, Moldenhauer, F, Carmona-Iragui, M, Huls, A, Sherman, SL, Strydom, A, de la Torre, R, Dierssen, M, Spanish Trisomy 21 Res Soc COVID-1. Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome. Journal of Clinical Medicine. 2021; 10(16)DOI:10.3390/jcm10163748. PMID:34442043. IF:4.964(Q2/4D).
01/08/2021
Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study
Carmona-Iragui, M, Alcolea, D, Barroeta, I, Videla, L, Munoz, L, Van Pelt, KL, Schmitt, FA, Lightner, DD, Koehl, LM, Jicha, G, Sacco, S, Mircher, C, Pape, SE, Hithersay, R, Clare, ICH, Holland, AJ, Nubling, G, Levin, J, Zaman, SH, Strydom, A, Rebillat, AS, Head, E, Blesa, R, Lleo, A, Fortea, J. Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. LANCET NEUROLOGY. 2021; 20(8)DOI:10.1016/S1474-4422(21)00129-0. PMID:34302785. IF:59.935(Q1/1D).
21/07/2021
Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies
Shi, L, Buckley, NJJ, Bos, I, Engelborghs, S, Sleegers, K, Frisoni, GB, Wallin, A, Lleo, A, Popp, J, Martinez-Lage, P, Legido-Quigley, C, Barkhof, F, Zetterberg, H, Visser, PJ, Bertram, L, Lovestone, S, Nevado-Holgado, AJ. Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience. 2021; 13DOI:10.3389/fnagi.2021.712545. PMID:34366831. IF:5.702(Q1/3D).
04/07/2021
Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition
Flores-Aguilar, L, Iulita, MF, Orciani, C, Tanna, N, Yang, JY, Bennett, DA, Cuello, AC. Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition. Journal of Neuroinflammation. 2021; 18(1)DOI:10.1186/s12974-021-02169-0. PMID:34218796. IF:9.589(Q1/1D).
01/07/2021
Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity
Altuna, M, Gimenez, S, Fortea, J. Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity. Journal of Clinical Medicine. 2021; 10(13)DOI:10.3390/jcm10132776. PMID:34202784. IF:4.964(Q2/4D).
01/07/2021
Sleep Disorders in Adults with Down Syndrome
Gimenez, S, Altuna, M, Blessing, E, Osorio, RM, Fortea, J. Sleep Disorders in Adults with Down Syndrome. Journal of Clinical Medicine. 2021; 10(14)DOI:10.3390/jcm10143012. PMID:34300177. IF:4.964(Q2/4D).
01/07/2021
Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-beta positivity
Tort-Merino, A, Valech, N, Laine, M, Olives, J, Leon, M, Ecay-Torres, M, Estanga, A, Martinez-Lage, P, Fortea, J, Molinuevo, JL, Sanchez-Valle, R, Rodriguez-Fornells, A, Rami, L. Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-beta positivity. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2021; 36(7)DOI:10.1002/gps.5539. PMID:33792089. IF:3.850(Q2/3D).